| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20039719 | HPV | ENSG00000122420.10 | protein_coding | PTGFR | No | No | 5737 | P43088 |
| TVIS20047382 | HPV | ENSG00000122420.10 | protein_coding | PTGFR | No | No | 5737 | P43088 |
| TVIS20025411 | HPV | ENSG00000122420.10 | protein_coding | PTGFR | No | No | 5737 | P43088 |
| TVIS44004630 | HTLV-1 | ENSG00000122420.10 | protein_coding | PTGFR | No | No | 5737 | P43088 |
| TVIS44033489 | HTLV-1 | ENSG00000122420.10 | protein_coding | PTGFR | No | No | 5737 | P43088 |
| TVIS44037299 | HTLV-1 | ENSG00000122420.10 | protein_coding | PTGFR | No | No | 5737 | P43088 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PTGFR |
|---|---|
| DrugBank ID | DB00654 |
| Drug Name | Latanoprost |
| Target ID | BE0000610 |
| UniProt ID | P43088 |
| Regulation Type | agonist |
| PubMed IDs | 14646172; 25328381; 8922563 |
| Citations | Nakajima T, Matsugi T, Goto W, Kageyama M, Mori N, Matsumura Y, Hara H: New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull. 2003 Dec;26(12):1691-5.@@Alm A: Latanoprost in the treatment of glaucoma. Clin Ophthalmol. 2014 Sep 26;8:1967-85. doi: 10.2147/OPTH.S59162. eCollection 2014.@@Patel SS, Spencer CM: Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging. 1996 Nov;9(5):363-78. doi: 10.2165/00002512-199609050-00007. |
| Groups | Approved; Investigational |
| Direct Classification | Prostaglandins and related compounds |
| SMILES | CC(C)OC(=O)CCCC=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 |
| Pathways | |
| PharmGKB | PA164774763 |
| ChEMBL | CHEMBL1051 |
